PUMA (XTRA:PUM) has caught investors’ attention after a mixed performance, with the stock showing gains over the past month and past 3 months, but a 1 year total return decline of 15.4%. See our ...
Zacks Investment Research on MSN
Puma Biotech (PBYI) Q4 earnings and revenues beat estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago. These figures ...
PUMA's Q2 and Q3 results were weak, but some of the pressure comes from the new CEO's cleanup strategy. PMMAF stock remains discounted, trading far cheaper than major peers like NIKE and adidas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results